The Biostatistics Core is a shared resource organized to meet the statistical needs of the USC Norris Comprehensive Cancer Center (NCCC) investigators. Statisticians in the Biostatistics Core collaborate with investigators in all the Cancer Center Programs - Molecular Genetics, Tumor Microenvironment, Epigenetics and Regulation, Developmental Therapeutics, Cancer Epidemiology, Cancer Control Research, Genitourinary Cancers, Gastrointestinal Cancers, Women's Cancers, and Leukemia and Lymphoma. The specific objectives of the Biostatistics Core are: 1. To provide statistical support to investigators at the NCCC in the design, planning, conduct, analysis, and reporting of cancer research studies 2. To ensure, in collaboration with members of the Clinical Investigations Support Office (CISO), the Cancer Research Informatics Core (CRIC), that clinical trials approved by the Clinical Investigations Committee (CIC) are properly executed and provide high quality clinical and translational research data, and ensure, in collaboration with the Translational Pathology Core (TPC) and CRIC, that disease-based databases and associated tumor banks, which serve as a resource for translational research, are supported and maintained 3. To adapt and incorporate, or develop, innovations in statistical and clinical trials methodology into the design and analysis of cancer research studies. Members of the Biostatistics Core participate in conceptualization and development of Cancer Center research projects, analyses for publications, development or adaptation of statistical methods, oversight and coordination activities, and other unanticipated needs of the Cancer Center. Core competencies include experimental design and data analysis, database design and utilization, and bioinformatics and analysis of high-throughput data. In the current application we are requesting partial funding for five Ph.D. statisticians, three M.S. level statisticians, and one Ph.D. level bioinformatician.
The use of modern statistical methods, analytic techniques, data processing and database design is an essential requirement of successful cancer clinical and translational research. The Biostatistics Core of the NCCC plays the central role in assuring that this requirement is fulfilled in research conducted by members of the Cancer Center.
|Bensman, Timothy J; Jayne, Jordanna G; Sun, Meiling et al. (2017) Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother 61:|
|Thomas, Duncan C (2017) Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer. Epidemiology 28:470-478|
|Thomas, Duncan C (2017) What Does ""Precision Medicine"" Have to Say About Prevention? Epidemiology 28:479-483|
|Schwitzer, Emily; Orlow, Irene; Zabor, Emily C et al. (2017) No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. Pigment Cell Melanoma Res 30:424-427|
|Okazaki, Satoshi; Stintzing, Sebastian; Sunakawa, Yu et al. (2017) Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer 141:1222-1230|
|Liang, Gangning; Weisenberger, Daniel J (2017) DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 12:416-432|
|Kim, Yong-Mi; Gang, Eun-Ji; Kahn, Michael (2017) CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Exp Hematol 52:1-11|
|Reid, Brett M; Permuth, Jennifer B; Chen, Y Ann et al. (2017) Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 26:116-125|
|Poulard, Coralie; Bittencourt, Danielle; Wu, Dai-Ying et al. (2017) A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP. EMBO Rep 18:1442-1459|
|Tokunaga, Ryuma; Zhang, Wu; Naseem, Madiha et al. (2017) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev 63:40-47|
Showing the most recent 10 out of 739 publications